Pharma Focus Asia

Valerion to Present Initial Clinical Data with VAL-1221 in Pompe Disease

Tuesday, February 06, 2018

Valerion Therapeutics, a clinical-stage biotechnology company that specializes in the development of therapies for orphan genetic diseases, today announced that a poster highlighting initial results from the first cohort of its ongoing Phase 1/2 clinical study with VAL-1221 in patients with late-onset Pompe disease will be presented at the 14th Annual WORLDSymposium™ 2018, being held February 5-9, 2018 in San Diego, CA.

"We are delighted to present these initial clinical findings from the first dosing cohort of our ongoing clinical study with VAL-1221 and look forward to providing further updates as the trial progresses into higher dosing cohorts," said Deborah Ramsdell, CEO of Valerion. "By targeting and clearing both lysosomal and extra-lysosomal glycogen in the cytoplasm, VAL-1221 has the potential to provide new therapeutic options to patients with late-onset Pompe disease."

Poster Presentation:

Treatment of Pompe Disease with VAL-1221 (Poster #323)
Wednesday, February 7, 2018 4:30 – 6:30p.m. PT
Valerion Therapeutics, Duke University Medical Center, University College London

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024